Dr. Victor Tapson has devoted his medical career to patient care, research, and teaching in pulmonary hypertension (PH) and pulmonary embolism. After fellowship, he co-founded the Duke Lung Transplant program, and simultaneously founded the Duke Pulmonary Vascular Disease Center, for pulmonary embolism and pulmonary hypertension. He served as clinical director of the lung transplant program for the next decade, and Director of the Pulmonary Vascular Disease Center for the next 20 years. He and his team conducted clinical trials and cared for patients as therapy evolved. In 2010, he was elected to the Royal College of Physicians.
In the field of venous thromboembolism, Dr. Tapson served on several of the ACCP Consensus Statements for Venous Thromboembolism (VTE), beginning in 1995. He served as Chairman for the ATS Consensus Statement and Clinical Practice Guidelines for the Diagnostic Approach to Acute VTE. He served as PI for the OPTALYSE PE study, the BiO2 IVCF study, and is co-PI PI for the world-wide TAFIa clinical trial in acute PE, as well as for the FLARE clot-extraction study, and is on the Steering Committee for the EXTRACT-PE trial and KNOCOUT PE Registry. He is on the steering committees for several other ongoing clinical trials, including SAFE-LYSE, EXTRACT-PE, and RESCUE. He has served as world-wide principal investigator (PI) or co-PI for many venous thromboembolism registries including DVT-FREE, IMPROVE, NABOR, ENDORSE. He is currently working with basic scientists on the development of two new venous thromboembolism therapeutic concepts. He has written several invited reviews for the New England Journal of Medicine. He has cared for thousands of patients with acute pulmonary embolism. Dr. Tapson is the first elected President of the U.S. Pulmonary Embolism Response Team Consortium. Based on his involvement in acute PE clinical trials and his interest in patient care, and as the founder of the Cedars-Sinai Pulmonary Embolism Response Team, Dr. Tapson sees acute pulmonary embolism patients nearly every day.
In pulmonary hypertension, he has served on steering committees for worldwide clinical trials in PH, including the epoprostenol trial (NEJM 1996), COMPASS-2, TRIUMPH, the FREEDOM studies, and the GRIPHON selexipag trial. He is currently on the steering committee / executive committee for the ralinepag clinical trials. His research has been NIH- and industry sponsored. He has cared for thousands of PH patients, having placed over 600 on parenteral therapy over the past 25 years. He has served on the steering committees for the World PH Guidelines (Venice, 2003, Dana Point, 2008, Nice, France, 2013 and Nice France 2018). He started the first PAH journal (Advances in PH). He also served on an invited expert panel for the 2017 NIH workshop entitled, “Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach: A Joint NHLBI–Cardiovascular Medical Research and Education Fund Workshop Report.”
In 2014, he left Duke for an outstanding opportunity at Cedars-Sinai Medical Center where he continues this work in pulmonary embolism and pulmonary hypertension. He just stepped down as the first elected president of the U.S. Pulmonary Embolism Response Team Consortium, a 501 (c)3 which is rapidly becoming an international organization. He continues to serve on the PERT Consortium board.